

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>ABBOTT LABORATORIES</u>	2. Date of Event Requiring Statement (Month/Day/Year) 04/20/2010	3. Issuer Name and Ticker or Trading Symbol <u>FACET BIOTECH CORP</u> [<u>FACT</u>]	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) _____ Other (specify below) _____	5. If Amendment, Date of Original Filed (Month/Day/Year)
			6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person
(Last) (First) (Middle) <u>100 ABBOTT PARK ROAD</u>			
(Street) <u>ABBOTT PARK</u> <u>IL</u> <u>60064</u>			
(City) (State) (Zip)			

Table I - Non-Derivative Securities Beneficially Owned			
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<u>Common Stock</u> ⁽¹⁾⁽²⁾	<u>19,257,669</u> ⁽³⁾	<u>D</u>	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)							
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			

1. Name and Address of Reporting Person* <u>ABBOTT LABORATORIES</u>
(Last) (First) (Middle) <u>100 ABBOTT PARK ROAD</u>
(Street) <u>ABBOTT PARK</u> <u>IL</u> <u>60064</u>
(City) (State) (Zip)
1. Name and Address of Reporting Person* <u>Amber Acquisition Inc.</u>
(Last) (First) (Middle) <u>100 ABBOTT PARK ROAD</u>
(Street) <u>ABBOTT PARK</u> <u>IL</u> <u>60064</u>
(City) (State) (Zip)

Explanation of Responses:

1. This form is a joint filing by Abbott Laboratories ("Abbott") and Amber Acquisition Inc., a wholly-owned subsidiary of Abbott (the "Purchaser").
2. This Form 3 relates to shares of common stock, par value \$0.01 per share (the "Common Stock"), and the associated preferred stock purchase rights issued in connection with the Rights Agreement, dated as of September 7, 2009, as amended by the amendments thereto dated as of December 15, 2009, December 16, 2009 and March 9, 2010, by and between Facet and Mellon Investor Services LLC (together with the Common Stock, the "Shares"), of Facet.
3. Reflects Shares of Facet purchased upon the expiration of a tender offer commenced pursuant to the Tender Offer Statement on Schedule TO, as amended or supplemented, initially filed with the Securities and Exchange Commission on March 23, 2010 by Abbott and the Purchaser. Amount includes 914,673 shares tendered through guaranteed delivery procedures.

/s/ Thomas C. Freyman
Executive Vice President,
Finance and Chief Financial 04/21/2010
Officer of Abbott Laboratories

/s/ Thomas C. Freyman 04/21/2010
President of Amber

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.